Azione HWEL HEALTHWELL ACQUISITION CORP. I
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Healthwell Acquisition Corp. I

Azioni

HWEL

US42227R1095

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Healthwell Acquisition Corp. I(NasdaqCM:HWEL) dropped from NASDAQ Composite Index
HEALTHWELL ACQUISITION CORP. I ANNOUNCES CANCELLATION OF SPECIAL STOCKHOLDER MEETING AND ITS INTENTION TO LIQUIDATE
Healthwell Acquisition Plans to Liquidate
Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate
Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I
Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.
Starton Therapeutics, Inc. cancelled the acquisition of Healthwell Acquisition Corp. I from a group of shareholders in a reverse merger transaction.
Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions
Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions
Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma
Top Premarket Gainers
Healthwell Acquisition Corp. I Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
Healthwell Acquisition I : Shareholder Director Nominations - Form 8-K
HEALTHWELL ACQUISITION CORP. I : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference
Healthwell Acquisition Corp. I Reports Earnings Results for the First Quarter Ended March 31, 2023
HEALTHWELL ACQUISITION CORP. I : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione HWEL
  4. Notizie Healthwell Acquisition Corp. I
  5. Altre lingue